# Oregon Measure 109

**Type:** State psilocybin regulation  
**Jurisdiction:** Oregon, USA  
**Status:** Active (approved 2020, implemented 2023)  
**Domain:** Psychedelic policy

## Overview

Measure 109 is Oregon's voter-approved ballot initiative establishing a state-regulated psilocybin services program. Passed in November 2020, it created the first legal framework in the United States for supervised psilocybin administration for therapeutic purposes outside of clinical trials.

## Regulatory Framework

- State licensing of psilocybin service centers
- Facilitator training and certification requirements
- Minimum protocol requirements for preparation, administration, and integration
- No medical diagnosis required for access
- Services available to adults 21+

## Implementation

The program became operational in 2023, with licensed service centers beginning to offer psilocybin sessions. Individual centers may exceed minimum regulatory requirements with enhanced screening, preparation, and integration protocols.

## Access and Equity Issues

First published outcomes data (Bendable Therapy, 2026) revealed significant demographic disparities:
- 87.5% of clients are white
- 84.1% have completed higher education
- 77.3% earn above $50K annually
- 46.6% travel from out of state
- Program functions partly as "psilocybin tourism" destination

These patterns indicate the program is not reaching underserved populations despite being designed for therapeutic mental health access.

## Clinical Outcomes

First naturalistic study (n=88, 30-day follow-up) showed large effect sizes:
- Depression: -4.63 points PHQ-8, d=0.90
- Anxiety: -4.85 points GAD-7, d=1.04
- Wellbeing: +10.67 points WHO-5, d=2.14
- Clinically significant HPPD at 30 days: 0%
- Lingering negative effects: 3.4%

## Timeline

- **2020-11** — Measure 109 approved by Oregon voters
- **2023** — Program implementation begins, licensed service centers open
- **2024-03** — First prospective outcomes study begins (Bendable Therapy)
- **2026-02-18** — First published outcomes study released as medRxiv preprint, revealing both strong clinical effects and significant demographic access disparities